Sumary of The race is on for medical treatment of NASH:
Rohit Loomba, MD, MHSc, director of the NAFLD Research Center and director of hepatology, professor of medicine at the University of California, San Diego, told Healio Gastroenterology that in the next decade NASH will likely become the No. 1 indication for liver transplantation.
According to Younossi, TE is much more pragmatic in the clinical setting.
COVID-19 seems more aggressive in patients with visceral obesity, especially morbid obesity, Younossi said, and these poor outcomes may be seen in patients with NAFLD and NASH.
Younossi said vitamin E is not FDA approved but is recommended by AASLD guidance for non-diabetic patients with NASH and no cirrhosis.